Name: PROTAC AR Degrader-4 TFA
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Solubility

DMSO: 200 mg/mL (226.24 mM)

Appearance

Solid

Storage

Store at -80°C

IUPACName

[(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] 2-[2-[2-[2-[[(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoyl]amino]ethoxy]ethoxy]ethoxy]acetate;2,2,2-trifluoroacetic acid

Synonyms

PROTAC AR Degrader-4 (TFA); PROTAC AR Degrader-4 TFA; HY-111848A; MS-31636; CS-0141488

InChI Key

URZFPFDMMGLCJC-AFGPOOCPSA-N

InChI

InChI=1S/C43H67N3O9.C2HF3O2/c1-28(2)24-36(46-41(51)39(49)35(44)25-29-8-6-5-7-9-29)40(50)45-18-19-52-20-21-53-22-23-54-27-38(48)55-37-13-12-33-32-11-10-30-26-31(47)14-16-42(30,3)34(32)15-17-43(33,37)4;3-2(4,5)1(6)7/h5-9,28,30,32-37,39,49H,10-27,44H2,1-4H3,(H,45,50)(H,46,51);(H,6,7)/t30-,32-,33-,34-,35+,36-,37-,39-,42-,43-;/m0./s1

SMILES

CC(C)CC(C(=O)NCCOCCOCCOCC(=O)OC1CCC2C1(CCC3C2CCC4C3(CCC(=O)C4)C)C)NC(=O)C(C(CC5=CC=CC=C5)N)O.C(=O)(C(F)(F)F)O

Mechanism

Target: Targets androgen receptor variants, including full-length AR and AR-V7 for experimental targeted protein degradation studies.

Binding Site: Binds the AR ligand-binding or variant-associated domain and E3 ligase ligand site to support productive ternary complex formation.

Mechanism of Action: PROTAC AR Degrader-4 TFA is designed for use in PROTAC or targeted protein degradation experiments directed toward androgen receptor variants, including full-length AR and AR-V7. The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.

Applications

• PROTAC-Mediated AR Degradation: This product facilitates the selective degradation of androgen receptors (AR) via the ubiquitin-proteasome system. By leveraging PROTAC technology, it provides a powerful tool for researchers studying AR-related pathways, enabling the investigation of AR's role in various cellular processes and disease states.

• Targeted Protein Degradation in Cancer Research: PROTAC AR Degrader-4 TFA is instrumental in cancer research, specifically in exploring therapeutic strategies against AR-driven cancers. It allows for the precise removal of AR, aiding in the discovery of novel cancer treatment mechanisms and the assessment of AR's contribution to tumorigenesis.

• Mechanistic Studies of AR Signaling: Utilizing this PROTAC compound, researchers can dissect the intricate signaling networks involving androgen receptors. It assists in elucidating AR's interactions and downstream effects, providing insights into its biological functions and potential as a therapeutic target.

• Drug Resistance Mechanism Exploration: This product is valuable for investigating mechanisms of drug resistance associated with AR. By enabling the degradation of AR, it helps uncover resistance pathways and contributes to the development of strategies to overcome therapeutic resistance in AR-related conditions.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂